Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 HIL-214 Norovirus GI.1/GII.4 Vaccine in Healthy Japanese Infants
jRCT2051230076Phase 1Completed
- Sponsor
- HilleVax
- Start
- Aug 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Noroviral gastroenteritis comparing HIL-214 vaccine with Placebo (2 arms). Primary endpoints: Solicited local reactions, Solicited systemic adverse events and 2 more. Started Aug 2023; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on jRCT2051230076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230076.